Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

JCOVDEN SUSPENSION INYECTABLE - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/JCOVDEN SUSPENSION INYECTABLE

Approved

STANDARD

JCOVDEN SUSPENSION INYECTABLE

Janssen-Cilag International N.V🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Mar 15, 2021
Approval ID: 8256fae8832b4a47
Company: Janssen-Cilag International N.V
Type: Standard

Approval Details

Approval Id: 8256fae8832b4a47
Drug Cima Aemps Name: JCOVDEN SUSPENSION INYECTABLE
Register Number: 1201525001
Holder Company Name: Janssen-Cilag International N.V
Marketing Company Name: Janssen Cilag S.A.
Holder Company Detail Path: /organization/janssen-cilag-international-nv
Authorization Date: 2021-03-15
Dosage Form: SUSPENSIÓN INYECTABLE
Dose: no menos de 8,92 Log10 U Inf/0,5 ml
Route Of Administration: VÍA INTRAMUSCULAR
Prescription Type: Medicamento Sujeto A Prescripción Médica
Commercialized: No
Company Name: Janssen-Cilag International N.V
Company Detail Path: /organization/janssen-cilag-international-nv

Company Information

Pharmaceutical Company Name: Janssen-Cilag International NV
Country Name: Belgium

Active Ingredients

VACUNA RECOMBINANTE (AD26) FRENTE A COVID-19 (J&J/JANSSEN)

8,92 Log10 unidades infecciosas (Inf.U)

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Mar 15, 2021

Approval ID

8256fae8832b4a47

Type

Standard

Back to CIMA-AEMPS Approvals